摘要
目的探究拉米夫定(LAM)联合阿德福韦酯(ADV)治疗乙型肝炎肝硬化的临床疗效。方法将2008年3月-2013年2月来我院就诊的48例乙型肝炎肝硬化患者根据治疗方法不同分为观察组和对照组,其中观察组24例,给予拉米夫定联合阿德福韦酯治疗,对照组24例,给予拉米夫定治疗,观察并比较治疗前后血清乙型肝炎病毒(HBV)DNA水平及主要肝功能指标变化情况。结果两组患者治疗12个月后血清HBV DNA水平及肝功能均有改善,观察组改善较为明显,差异有统计学意义(P<0.05),观察组治疗12个月后血清HBV DNA转阴率相比对照组有统计学差异(P<0.01)。结论拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化疗效较好,肝功能改善明显,值得在临床上予以推广。
Objective To explore the clinical efficacy of lamivudine（LAM） combined with adefovir dipivoxil（ADV） in the treatment of hepatitis B cirrhosis. Methods Forty-eight cases with hepatitis B cirrhosis admitted into our hospital from March 2008 to February 2013 were divided into the observation group and the control group according to different treatment methods, of which 24 cases in the observation group were given lamivudine combined with adefovir dipivoxil treatment, 24 patients in the control group was given lamivudine treatment. The serum hepatitis B virus （HBV） DNA levels and major liver function indexes changes of two groups before and after the treatment were observed and compared. Results The serum HBV DNA Lvels and liver function of patients in two groups after 12 months of treatment improved, while the improvement in thd observation group was more obvious, the differences were statistically significant between two groups （P 〈 0.05）. There was significant different in the negative conversion rate of serum HBV DNA after 12 months of treatment between two groups （P 〈 0.01）. Conclusion Lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis has better efficacy, significant improvement of liver function, and it is worthy of clinical promotion.
出处
《中国医药科学》
2013年第20期57-58,共2页
China Medicine And Pharmacy
